```html

Yaws‑like Leprosy (Mycobacterium leprae Infection)

Overview

Yaws‑like leprosy is a clinical variant of leprosy (also called Hansen’s disease) that presents with skin lesions resembling those of yaws, a non‑syphilitic treponemal infection. The underlying pathogen is Mycobacterium leprae, a slow‑growing bacterium that primarily targets peripheral nerves and skin. This form is most often seen in individuals with the borderline or tuberculoid spectrum of leprosy, where the immune response is robust enough to limit widespread disease but insufficient to eradicate the organism completely.

Leprosy remains a disease of poverty, affecting people who live in conditions with inadequate housing, limited access to health care, and frequent exposure to infected individuals. According to the World Health Organization (WHO), an estimated 202,000 new cases were reported globally in 2022, with the majority from India, Brazil, and Indonesia.<sup>[1]</sup> Yaws‑like presentations constitute a small proportion—approximately 5‑10%—of all leprosy cases, but they are significant because their atypical appearance can delay diagnosis.

Symptoms

The clinical picture combines classic leprosy features with yaws‑type skin lesions. Symptoms may vary according to the immunologic classification (tuberculoid, borderline, lepromatous). The most common findings are:

• Hypopigmented or erythematous macules—flat, often painless patches with well‑defined borders; the skin may feel cooler than surrounding tissue.
• Yaws‑like plaques—raised, thickened lesions that can be verrucous (wart‑like) or ulcerated, resembling yaws gummas.
• Hair loss (alopecia) within lesions—a hallmark of leprosy due to nerve involvement.
• Loss of sensation—reduced heat, pain, or touch perception in the affected skin; this is a key differentiator from yaws.
• Peripheral nerve enlargement—palpable thickening of nerves (e.g., ulnar, common peroneal) that may cause weakness or numbness in the hand/foot.
• Muscle weakness—usually focal, reflecting nerve damage (e.g., claw hand, foot drop).
• Neuropathic pain—burning or tingling sensations, especially at night.
• Eye involvement—dryness, reduced blinking, or corneal ulceration if facial nerves are affected.
• Systemic signs—rarely fever, weight loss, or malaise in multibacillary disease.

Because the skin lesions can be mistaken for fungal infections, psoriasis, or yaws, careful neurological assessment is essential.

Causes and Risk Factors

Cause

Leprosy is caused by the obligate intracellular bacterium Mycobacterium leprae. The organism has a very slow replication rate (doubling time ≈ 14 days) and preferentially infects Schwann cells of peripheral nerves and macrophages in the skin.

Transmission

• Respiratory droplets from untreated patients with high bacterial loads (especially multibacillary leprosy).
• Skin-to-skin contact with lesions that harbor bacilli.
• Animal reservoirs (e.g., armadillos) have been linked to sporadic cases in the southern United States, though this is uncommon worldwide.

Risk Factors

• Living in endemic regions with >1 case per 10,000 population.
• Close, prolonged contact with an untreated leprosy patient.
• Poor socioeconomic status, overcrowding, and lack of sanitation.
• Genetic susceptibility: certain HLA‑DR and TLR polymorphisms increase risk.
• Compromised immunity (e.g., HIV, diabetes) may predispose to multibacillary disease.

Diagnosis

Accurate diagnosis relies on a combination of clinical assessment, laboratory tests, and occasionally imaging.

Clinical Evaluation

• Detailed skin examination to document lesion type, distribution, and sensory testing.
• Palpation of peripheral nerves for thickening and tenderness.
• Neurological assessment (muscle strength, reflexes, sensory mapping).

Laboratory Tests

• Skin slit‑smear microscopy—Ziehl‑Neelsen stain to detect acid‑fast bacilli; positivity correlates with bacterial load.
• Skin biopsy—histopathology shows granulomas, nerve involvement, and presence of bacilli; special stains (Fite‑Faraco) highlight M. leprae.
• Polymerase chain reaction (PCR)—detects bacterial DNA in skin or nerve tissue; highly sensitive, especially in paucibacillary cases.
• Serology—anti‑PGL‑1 (phenolic glycolipid‑1) antibodies can indicate exposure, but are not definitive for diagnosis.

Classification

The Ridley‑Jopling classification (tuberculoid, borderline, lepromatous) guides therapy. Yaws‑like leprosy most often falls into the borderline tuberculoid (BT) or borderline borderline (BB) categories.

Treatment Options

The World Health Organization recommends multidrug therapy (MDT) for all forms of leprosy. The regimen is tailored to disease classification.

Multidrug Therapy (MDT)

Form	Drugs (Monthly Dose)	Duration
Paucibacillary (PB) – ≤5 skin lesions, negative smear	Rifampicin 600 mg + Dapsone 100 mg	6 months
Multibacillary (MB) – >5 lesions or positive smear	Rifampicin 600 mg + Dapsone 100 mg + Clofazimine 300 mg	12 months (WHO now recommends 12 months for all MB cases)

All medicines are administered under direct observation to ensure adherence.

Adjunctive Treatments

• Prednisone (or other corticosteroids) for acute neuritis or severe inflammation—typically 0.5–1 mg/kg/day, tapered over 12 weeks.
• Physiotherapy to preserve muscle strength and prevent contractures.
• Protection of anesthetic areas (e.g., regular skin inspection, use of protective footwear).

Lifestyle & Supportive Measures

• Good nutrition (adequate protein, vitamins A, D, and B12) to support immune function.
• Smoking cessation and limiting alcohol, which can impair wound healing.
• Regular follow‑up with a leprosy‑experienced clinician, especially during the first year of therapy.

Living with Yaws‑like Leprosy (M. leprae Infection)

While the disease is curable, the chronic nature of nerve damage requires ongoing self‑care.

Daily Skin Care

• Inspect all skin daily, especially anesthetic patches, for cuts, burns, or infection.
• Keep lesions clean with mild soap and water; avoid harsh scrubbing.
• Apply barrier creams (e.g., zinc oxide) to prevent dryness and cracking.

Foot Protection

• Wear sturdy, closed shoes with a thick sole; change socks daily.
• Use orthotic inserts if foot deformities develop.
• Check feet after walking, especially on rough surfaces.

Neurological Monitoring

• Perform a brief sensory test (light touch with a cotton swab) on affected areas each week.
• Report any new numbness, tingling, or weakness promptly.

Psychosocial Support

• Join local or online leprosy support groups to combat stigma.
• Seek counseling if anxiety or depression arises; many NGOs provide free mental‑health services.
• Educate family and friends about the disease to reduce isolation.

Adherence Strategies

• Set a weekly reminder for medication intake.
• Use a medication diary or mobile app to track doses.
• Engage a treatment supporter (family member or community health worker).

Prevention

• Early case detection and prompt MDT reduce bacterial load and transmission.
• Close‑contact prophylaxis: A single dose of rifampicin (10 mg/kg) given to household contacts within 2 weeks of diagnosing an index case reduces the risk of developing leprosy by ~60% (WHO 2020 recommendation).<sup>[2]</sup>
• Improving housing, ventilation, and sanitation in endemic communities.
• Health‑education campaigns that emphasize that leprosy is not highly contagious and is curable.
• Vaccination research: the Mycobacterium indicus BCG vaccine offers partial protection; BCG is recommended for newborns in many endemic countries.

Complications

If left untreated or if nerve damage is not addressed, several serious complications may arise:

• Permanent peripheral neuropathy leading to loss of sensation, muscle weakness, and deformities (claw hand, foot drop).
• Ulceration and secondary infection of insensitive skin, which can progress to osteomyelitis.
• Eye disease (lagophthalmos, corneal ulcer, blindness) due to facial nerve involvement.
• Severe reactions – Type 1 (reversal) or Type 2 (erythema nodosum leprosum) immune reactions causing painful swelling, fever, and organ involvement.
• Social stigma and psychological distress, affecting employment, education, and relationships.

When to Seek Emergency Care

---

References

1. World Health Organization. Global Leprosy Report 2022. Geneva: WHO; 2023.
2. World Health Organization. “Single dose rifampicin for contacts of leprosy patients” – WHO Technical Report Series No. 1013, 2020.
3. Mayo Clinic. Leprosy (Hansen disease) – Symptoms, Diagnosis, and Treatment. https://www.mayoclinic.org/diseases-conditions/leprosy
4. Centers for Disease Control and Prevention. Leprosy (Hansen Disease) – Fact Sheet. https://www.cdc.gov/leprosy
5. Cleveland Clinic. Leprosy: Overview, Causes, and Management. https://my.clevelandclinic.org/health/diseases/17059-leprosy

```